CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells for B-cell Acute Lymphoblastic Leukemia
Study Summary
This trial will study a new cancer treatment that uses a person's own immune cells to target and kill cancer cells. The treatment will be given to patients who have been previously excluded from other trials, such as children with cancer.
- B-cell Acute Lymphoblastic Leukemia
- Non-Hodgkin's Lymphoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: 5 years
Trial Safety
Trial Design
1 Treatment Group
UCD19 CART infusion
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 30 - 25 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants have been recruited for this clinical experiment?
"Confirmed, the clinical trial is still open for enrollment. It was first posted on February 24th 2021 with its most recent update occurring November 9th 2022. The project hopes to enroll 50 individuals from 1 medical centre." - Anonymous Online Contributor
Does this research have any age restrictions?
"This medical trial is open to participants who are between 30 days and 25 years of age." - Anonymous Online Contributor
What requirements must be met in order to enlist for this medical study?
"This clinical trial demands that all participants be between 1 month and 25 years old, with a diagnosis of diffuse lymphoma. Additionally, the total number of patients sought is fifty (50)." - Anonymous Online Contributor
Are there still vacancies to take part in this analysis?
"Yes, the clinicaltrials.gov website confirms that this research is actively trying to recruit individuals for participation. Initially posted on February 24th 2021 and recently modified on November 9th 2022, this medical trial seeks 50 participants at a single location." - Anonymous Online Contributor